AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28492195 — intervention group
Group type: COMPARATOR
Intervention: Inhalation route of administration
Number of subjects: 60
Study 26147295 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 15102
Study 26147295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15102
Study 23273434 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.5 mg/m² biweekly on days 1, 4, 8, and 11 of a 21-day cycle (arm A)
Number of subjects: 87
Study 23273434 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib 1.6 mg/m² weekly on days 1, 8, 15, and 22 of a 35-day cycle (arm B)
Number of subjects: 87
Study 21641773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnumbered questionnaire
Number of subjects: 0
Study 21641773 — intervention group
Group type: COMPARATOR
Intervention: Numbered questionnaire
Number of subjects: 0
Study 18820852 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with keto-amino acids (100 mg/kg BW per day)
Number of subjects: 111
Study 18820852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 16855170 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha monoclonal antibody infliximab
Number of subjects: 7
Study 16855170 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 patients on other anti-TNF therapies and 20 negative controls)
Number of subjects: 7
Study 15733432 — intervention group
Group type: EXPERIMENTAL
Intervention: Array IOL
Number of subjects: 255
Study 15733432 — intervention group
Group type: COMPARATOR
Intervention: Monofocal Hydroview IOL
Number of subjects: 255
Study 11286539 — intervention group
Group type: COMPARATOR
Intervention: Four 5-day IL-2 cycles every 8 weeks (control)
Number of subjects: 22
Study 11286539 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of longer duration (mean 7.7-days)
Number of subjects: 22
Study 11286539 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency of 5-day cycles (every 4.1 weeks on average)
Number of subjects: 22
Study 9029744 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5-cm2 once-a-week adhesive patch
Number of subjects: 0
Study 9029744 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-cm2 once-a-week adhesive patch
Number of subjects: 0
Study 9029744 — intervention group
Group type: COMPARATOR
Intervention: 10-cm2 twice-a-week Estraderm patch
Number of subjects: 0
Study 9029744 — intervention group
Group type: COMPARATOR
Intervention: 20-cm2 twice-a-week Estraderm patch
Number of subjects: 0
Study 7973004 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin therapy
Number of subjects: 0
Study 7973004 — intervention group
Group type: COMPARATOR
Intervention: Mineral components
Number of subjects: 0
Study 3263890 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of prednisone given daily for 5 days
Number of subjects: 0
Study 3263890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30684954 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitude towards conducting research
Number of subjects: 200
Study 30684954 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers encountered during research
Number of subjects: 200
Study 30684954 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient research allotted time
Number of subjects: 200
Study 30684954 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient financial support
Number of subjects: 200
Study 30684954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of financial incentives
Number of subjects: 200
Study 30684954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of statistical support
Number of subjects: 200
Study 30684954 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians designation and board certificate
Number of subjects: 200
Study 28502831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (333.3 mg, encapsulated, 3x/day at mealtimes)
Number of subjects: 47
Study 28502831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28502831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 47
Study 25567656 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited fluid resuscitation combined with blood pressure-controlling drugs
Number of subjects: 51
Study 25567656 — intervention group
Group type: COMPARATOR
Intervention: Traditional fluid resuscitation (conventional group)
Number of subjects: 51
Study 22923230 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 11
Study 22923230 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% N(2)
Number of subjects: 11
Study 22923230 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CO(2) + 90% N(2)
Number of subjects: 11
Study 22923230 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of breathing after apnoea
Number of subjects: 11
Study 22923230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory-capacity apnoea with various gases
Number of subjects: 11
Study 21443994 — intervention group
Group type: EXPERIMENTAL
Intervention: Latino Dietary Behaviors Questionnaire (LDBQ) intervention group
Number of subjects: 252
Study 21443994 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study 19224793 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (P)
Number of subjects: 60
Study 19224793 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (R)
Number of subjects: 60
Study 16732710 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily corticosteroids
Number of subjects: 0
Study 16732710 — intervention group
Group type: COMPARATOR
Intervention: Intermittent corticosteroids
Number of subjects: 0
Study 12911327 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 98
Study 12911327 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol (beta-blocker)
Number of subjects: 98
Study 10973679 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2.8‐4.2)
Number of subjects: 40
Study 10973679 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg daily
Number of subjects: 40
Study 10973679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Warfarin and Aspirin)
Number of subjects: 40
Study 9069728 — intervention group
Group type: EXPERIMENTAL
Intervention: X-rays initiated at triage
Number of subjects: 175
Study 9069728 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (no X-rays initiated at triage)
Number of subjects: 175
Study 8438096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol controlled release (SCR) 8 mg b.d.
Number of subjects: 0
Study 8438096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3300762 — intervention group
Group type: EXPERIMENTAL
Intervention: Total or subtotal nodal irradiation
Number of subjects: 142
Study 29890985 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Neuromuscular Taping (NMT)
Number of subjects: 40
Study 29890985 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 40
Study 28359212 — intervention group
Group type: EXPERIMENTAL
Intervention: pACP intervention (three 60-minute sessions scheduled one week apart)
Number of subjects: 105
Study 28359212 — intervention group
Group type: EXPERIMENTAL
Intervention: pACP intervention
Number of subjects: 105
Study 28359212 — intervention group
Group type: COMPARATOR
Intervention: Active control (developmental history, safety tips, nutrition and exercise education)
Number of subjects: 105
Study 26242401 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive VRET plus conventional analgesics
Number of subjects: 25
Study 26242401 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive VRET with conventional analgesics
Number of subjects: 25
Study 26242401 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesics alone
Number of subjects: 25
Study 24503402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux with tirofiban
Number of subjects: 389
Study 24503402 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin with tirofiban
Number of subjects: 389
Study 21120152 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 16
Study 21120152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17846044 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 391
Study 17846044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 17032093 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about personal benefits resulting from the transgression
Number of subjects: 304
Study 17032093 — intervention group
Group type: COMPARATOR
Intervention: Writing about traumatic features of the transgression
Number of subjects: 304
Study 17032093 — intervention group
Group type: COMPARATOR
Intervention: Writing about a control topic unrelated to the transgression
Number of subjects: 304
Study 12743142 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-pelvic radiotherapy (WP RT) + Neoadjuvant combined androgen suppression (NCHT)
Number of subjects: 1323
Study 12743142 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only radiotherapy (PO RT) + Neoadjuvant combined androgen suppression (NCHT)
Number of subjects: 1323
Study 12743142 — intervention group
Group type: COMPARATOR
Intervention: Whole-pelvic radiotherapy (WP RT) + Adjuvant hormonal therapy (AHT)
Number of subjects: 1323
Study 12743142 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only radiotherapy (PO RT) + Adjuvant hormonal therapy (AHT)
Number of subjects: 1323
Study 12743142 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combined androgen suppression (NCHT)
Number of subjects: 1323
Study 12743142 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant hormonal therapy (AHT)
Number of subjects: 1323
Study 12743142 — intervention group
Group type: COMPARATOR
Intervention: All four arms (WP RT + NCHT, PO RT + NCHT, WP RT + AHT, PO RT + AHT)
Number of subjects: 1323
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscope-guided tracheal intubation (free-floating)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscope-guided tracheal intubation (restrained)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscope-guided tracheal intubation (poolside)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (poolside)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (free-floating)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (restrained)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (poolside)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (free-floating)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (restrained)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (poolside)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (free-floating)
Number of subjects: 4
Study 10781267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (restrained)
Number of subjects: 4
Study 8899314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain medication
Number of subjects: 32
Study 8899314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Ukrain)
Number of subjects: 32
Study 2027922 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (M; 2.3% delta‐9‐THC) with 20 s breathhold
Number of subjects: 10
Study 2027922 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana (P; 0.0% delta‐9‐THC) with 20 s breathhold
Number of subjects: 10
Study 2027922 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (M; 2.3% delta‐9‐THC) with no breathhold
Number of subjects: 10
Study 2027922 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana (P; 0.0% delta‐9‐THC) with no breathhold
Number of subjects: 10
Study 6385356 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir combined with dilute betamethasone
Number of subjects: 0
Study 6385356 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside combined with dilute betamethasone
Number of subjects: 0
Study 31830294 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (IOL) implantation in study cases with previous ocular surgeries
Number of subjects: 133
Study 29788433 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (400 g daily for 2 weeks)
Number of subjects: 14
Study 29788433 — intervention group
Group type: COMPARATOR
Intervention: Nonfermented milk (400 g daily for 2 weeks)
Number of subjects: 14
Study 27565902 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 13935
Study 27565902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13935
Study 24890124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprobe sampling
Number of subjects: 77
Study 24890124 — intervention group
Group type: COMPARATOR
Intervention: Conventional forceps sampling
Number of subjects: 77
Study 22130786 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 169
Study 22130786 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 μg)
Number of subjects: 169
Study 22130786 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene + Alfacalcidol (R + D)
Number of subjects: 169
Study 19875998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 2273
Study 19875998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 2273
Study 19875998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both higher BMI and waist circumference
Number of subjects: 2273
Study 19875998 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and waist circumference
Number of subjects: 2273
Study 18472528 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse without alcohol
Number of subjects: 21
Study 18472528 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouth rinse with alcohol
Number of subjects: 21
Study 16344019 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture (including electroacupuncture), mean 16.9 sessions over 10.5 weeks
Number of subjects: 33
Study 16344019 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 33
Study 12161329 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated trials of familiar leg bicycling exercise with dead-space induced hypercapnia
Number of subjects: 0
Study 12161329 — intervention group
Group type: COMPARATOR
Intervention: Control paradigms involving either repeated exercise alone or resting dead space alone
Number of subjects: 0
Study 10628889 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4-6 mg/day)
Number of subjects: 347
Study 10628889 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (50-100 mg/day)
Number of subjects: 347
Study 10628889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 347
Study 8688982 — intervention group
Group type: EXPERIMENTAL
Intervention: Skenan (30 mg)
Number of subjects: 12
Study 8688982 — intervention group
Group type: COMPARATOR
Intervention: Moscontin (30 mg)
Number of subjects: 12
Study 2091623 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (400 to 1600 mg)
Number of subjects: 5
Study 2091623 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 5
Study 7350799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized terbutaline (0.5 mg)
Number of subjects: 12
Study 7350799 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (0.5 mg)
Number of subjects: 12
Study 7350799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31038809 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning pain modulation at 30% of PTT
Number of subjects: 20
Study 31038809 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning pain modulation at 70% of PTT
Number of subjects: 20
Study 31038809 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning pain modulation at 100% of PTT
Number of subjects: 20
Study 31038809 — intervention group
Group type: COMPARATOR
Intervention: No conditioning (baseline and post-recordings)
Number of subjects: 20
Study 27734305 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 16
Study 27734305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27734305 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 16
Study 26063588 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on introducing five vegetables (one per day) as first foods repeated over 15 days
Number of subjects: 146
Study 26063588 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 146
Study 23335357 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ferric carboxymaltose (FCM; two injections of 750 mg)
Number of subjects: 0
Study 23335357 — intervention group
Group type: COMPARATOR
Intervention: Oral iron therapy
Number of subjects: 0
Study 21514093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone at 1.5 μg/kg per minute (STRESS)
Number of subjects: 0
Study 21514093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone at 3.0 μg/kg per minute (PHARM)
Number of subjects: 0
Study 21514093 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 19517601 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural physical factors (sun, air, and sea water baths) in specialized children's sanatoria (group 1, n = 278)
Number of subjects: 556
Study 19517601 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in municipal outpatient settings (group 2, n = 278)
Number of subjects: 556
Study 17096851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical anterior discectomy without fusion
Number of subjects: 270
Study 17096851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical anterior discectomy with fusion using a stand alone cage
Number of subjects: 270
Study 17096851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical anterior discectomy with implantation of a Bryan's disc prosthesis
Number of subjects: 270
Study 17096851 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 270
Study 15150487 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (simvastatin and pravastatin)
Number of subjects: 0
Study 15150487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11356728 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic
Number of subjects: 301
Study 11356728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 9067046 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1)
Number of subjects: 90
Study 9067046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 90
Study 7960904 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 954
Study 7960904 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 954
Study 7960904 — intervention group
Group type: EXPERIMENTAL
Intervention: All cholecystectomy patients
Number of subjects: 954
Study 3595575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrozepin 10 mg
Number of subjects: 90
Study 3595575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 90
Study 3595575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30045356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT) combined with McIsaac clinical score
Number of subjects: 605
Study 30045356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT)
Number of subjects: 605
Study 30045356 — intervention group
Group type: EXPERIMENTAL
Intervention: McIsaac score of 3 or more
Number of subjects: 605
Study 28688514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (CEA)
Number of subjects: 98
Study 28688514 — intervention group
Group type: COMPARATOR
Intervention: Continuous preperitoneal wound catheters (CPA)
Number of subjects: 98
Study 28688514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CPA and CEA)
Number of subjects: 98
Study 27338997 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (integrated intervention for T2DM and depression employing patient prioritized planning)
Number of subjects: 78
Study 27338997 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention (integrated intervention alone)
Number of subjects: 78
Study 25549238 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal HBV vaccination
Number of subjects: 39292
Study 25549238 — intervention group
Group type: COMPARATOR
Intervention: Catch-up vaccination
Number of subjects: 39292
Study 25549238 — intervention group
Group type: COMPARATOR
Intervention: Booster at age 10-14 years
Number of subjects: 39292
Study 22152671 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Category Implicit Association Tests (SC‐IATs) for alcohol
Number of subjects: 378
Study 22152671 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of substance use
Number of subjects: 378
Study 19630495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol in addition to narcotic pain medications
Number of subjects: 50
Study 19630495 — intervention group
Group type: COMPARATOR
Intervention: Narcotics and acetaminophen alone
Number of subjects: 50
Study 18769906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate (1 g)
Number of subjects: 12
Study 18769906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17230043 — intervention group
Group type: EXPERIMENTAL
Intervention: KYSt‐4 (Nohime) strawberry variety
Number of subjects: 2